When did ArriVent BioPharma, Inc. report Q4 2024 earnings?

ArriVent BioPharma, Inc. (AVBP) reported Q4 2024 earnings on March 3, 2025 before market open.

What were ArriVent BioPharma, Inc.'s Q4 2024 revenue and EPS?

ArriVent BioPharma, Inc. reported eps of $-0.60 for Q4 2024.

Did ArriVent BioPharma, Inc. beat estimates in Q4 2024?

EPS beat the consensus estimate of $-0.78 by $0.18.

Where can I find ArriVent BioPharma, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001558370-25-001999) directly on SEC EDGAR. The filing index links above go to sec.gov.

ArriVent BioPharma, Inc. AVBP Q4 2024 Annual earnings

Reported March 3, 2025 · Before market open

EPS-$0.60Beat by $0.18

EPS estimate-$0.78

Next report

Aug 14, 2026 (In 2 weeks)

EPS estimate-$0.98

Financials

Q4 2024

Income statement

See full

Operating income-$23.7M-2.5%

Net income-$20.6M+2.6%

EPS (diluted)-$0.61+92.1%

Balance sheet

See full

Cash & equivalents$74.3M-50.6%

Total debt$176.0K-44.5%

Total equity$257.7M+268%

Total assets$274.9M+68.6%

Cash flow

See full

Operating cash flow-$16.2M-8.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$897.69M—

Enterprise value$823.58M—

Returns & leverage

See full

Debt / equity0×—

Current ratio13.1×-0.6×

Versus estimates

Diluted EPS

Q1 2026-$0.96Miss by $0.08 Q4 2025-$0.78Beat by $0.09 Q3 2025-$0.83Miss by $0.05 Q2 2025-$0.90Miss by $0.20 Q1 2025-$1.90Miss by $1.24

Q4 2024-$0.60Beat by $0.18

Ask the moment ArriVent BioPharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ArriVent BioPharma, Inc. report Q4 2024 earnings?: ArriVent BioPharma, Inc. (AVBP) reported Q4 2024 earnings on March 3, 2025 before market open.
What were ArriVent BioPharma, Inc.'s Q4 2024 revenue and EPS?: ArriVent BioPharma, Inc. reported eps of $-0.60 for Q4 2024.
Did ArriVent BioPharma, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.78 by $0.18.
Where can I find ArriVent BioPharma, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-001999) directly on SEC EDGAR. The filing index links above go to sec.gov.